

# Health Care: Pharmaceuticals, Biotechnology and Life Sciences

## Longeveron Inc. (LGVN)

**ESTIMATE CHANGES** 

August 15, 2022

# LGVN: Updating Model Following 2Q Results

We are maintaining our Buy rating and \$20 (peak sales-based) price target on LGVN. The company reported 2Q results on Friday, with 2Q operating expenses of \$4.4M versus our \$5.4M estimate. 2Q revenue of \$0.5M exceeded our \$0.2M estimate, on higher clinical trial revenue than we had modeled. LGVN finished 2Q with \$27.0M in cash and short term investments, which is expected to enable LGVN to fund operations into the first half of 2024.

Key operational updates. LGVN's Phase2a study for Lomecel-B for the treatment of mild Alzheimer's is at 50% enrollment and management expects to enroll the remainder of patients on schedule (by the end of 2022). LGVN's Phase 2a study (ELPIS II) of Lomecel-B in infants with Hypoplastic Left Heart Syndrome (HLHS) continues to enroll patients; we expect enrollment to continue into 2023. We remind investors that the HLHS program remains the primary driver of our LGVN price target. LGVN's Aging Frailty (AF) amended study design was accepted by Japanese regulators, enabling that trial to commence. LGVN also reported that its Phase 1/2 HERA trial (influenza vaccine in combination with Lomecel-B) met the primary endpoint for safety in the randomized placebo-control portion of the study.

**Updating estimates.** We are narrowing our 2022 EPS loss estimate to (\$0.94) from (\$0.99) on slightly lower operating expense assumptions (we are modeling \$19.1M in operating expenses in 2022). We are narrowing our 2023 EPS loss estimate from (\$1.24) to (\$1.17).

**On deck.** Upcoming catalysts include the completion of Alzheimer's enrollment, the first patient enrollment in the Japanese Phase 2 study of Lomecel-B in AF, and the publications of both the HLHS ELIPS I study and the completed Phase 2b study in Adult Frailty in peer reviewed medical journals.


**Risks.** The FDA has not yet approved an MSC-derived cell-therapy product. AF lacks a concrete consensus definition, which could hinder the advancement of Lomecel-B into late stage development for AF. The long-term commercial potential of any COVID-related efforts, such as the ARDS program, remains uncertain given the competitive landscape as well as the evolving nature of COVID-19. The landscape for novel AD treatments is crowded and is characterized in part by new technologies that maybe more advanced in development than Lomecel-B. The failure of peer cell-therapy programs could have a negative impact on group sentiment.

Constantine Davides, CFA cdavides@efhuttongroup.com

MARKET DATA	
Rating	Buy
Price Target	\$20.00
Price	\$5.95
Average Daily Volume	221
Market Cap (\$M)	\$124.7
Enterprise Value (\$M)	\$97.6
Dividend Yield	0.0%

ESTIMATES							
		2021A	2022E	2023E			
EPS	Q1	(0.18)	(0.17)	-			
	Q2	(0.26)	(0.27)	-			
	prev:	-	(0.26)	-			
	Q3	(0.25)	(0.24)	-			
	prev:	-	(0.27)	-			
	Q4	(0.20)	(0.26)	-			
	prev:	-	(0.29)	-			
	FY	(0.90)	(0.94)	(1.17)			
	prev:	-	(0.99)	(1.24)			

#### One Year Performance Chart







#### **Important Disclosures**

### **Analyst Certification**

I, Constantine Davides, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

## Company-Specific Disclosures

EF Hutton, division of Benchmark Investments, LLC or its affiliates received compensation from Longeveron Inc for investment banking services within the past twelve months, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report

#### General Disclosures

This report has been produced by EF Hutton, division of Benchmark Investments, LLC and is for informational purposes only. It does not constitute solicitation of the sale or purchase of securities or other investments. The information contained herein is derived from sources that are believed to be reliable. Prices, numbers, and similar data contained herein include past results, estimates, and forecasts, all of which may differ from actual data. These prices, numbers, and similar data may also change without prior notification. This research report does not guarantee future performance, and the information contained herein should be used solely at the discretion and responsibility of the client. Neither EF Hutton nor its affiliates accept any liability or responsibility for any results in connection with the use of such information. This research report does not consider specific financial situations, needs, or investment objectives of any client, and it is not intended to provide tax, legal, or investment advice. Clients are responsible for making final investment decisions and should do so after a careful examination of all documentation delivered prior to execution, explanatory documents pertaining to listed securities, etc., prospectuses, and other relevant documents. EF Hutton and its affiliates may make investment decisions based on this research report. In addition, EF Hutton and its affiliates, as well as employees, may trade in the securities mentioned in this research report, their derivatives, or other securities issued by the same issuing companies in this research report. This research report is distributed by EF Hutton and/or its affiliates. The information contained herein is for client use only.

EF Hutton holds the copyright on this research report. Any unauthorized use or transmission of any part of this research report for any reason, whether by digital, mechanical, or any other means, is prohibited. If you have any questions, please contact your sales representative. Additional information is available upon request.

Certain company names, product and/or service names that appear in this research report are trademarks or registered trademarks of EF Hutton or other companies mentioned in the report.

Copyright 2022 EF HUTTON, division of Benchmark Investments, LLC.

EF Hutton rating definitions are expressed as the total return relative to the expected performance of S&P 500 over a 12-month period.

**BUY (B)** - Total return expected to exceed S&P 500 by at least 10%

**HOLD (H)** - Total return expected to be in-line with S&P 500


**SELL (S)** - Total return expected to underperform S&P 500 by at least 10%

# Distribution of Ratings/IB Services EF Hutton

			IB Serv./Pa	1B Serv./Past 12 Mos.		
Rating	Count	Percent	Count	Percent		



#### Longeveron Inc. Rating History as of 08/12/2022



EF Hutton, division of Benchmark Investments, LLC or its affiliates received compensation from Longeveron Inc for investment banking services within the past twelve months, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report

